Webcast - Renal Cell Carcinoma

This continuing education (CE) activity features recorded lectures and discussions from our recent live webcast Renal Cell Carcinoma: Current and Emerging Standards in Systemic Therapy. This activity is intended to improve the care of kidney cancer patients by educating oncologists, nurses, pharmacists, and other healthcare providers about the latest developments in the field. Expert faculty share patient case scenarios commonly encountered in clinical practice and provide learners practical methods to optimize therapy.

In this meeting faculties review and discuss emerging data across the spectrum of kidney cancer management, from early stage to metastatic disease. The panel of experts also discuss how they are applying this information to their practices right now, as well as potential future implications.

REGISTRATION FEES: 

Registration is free for healthcare providers who are NOT employees of ACCME defined ineligible companies. Please proceed to registration and select "non-industry learner" if you are a healthcare provider involved in patient care and are not an employee of an ineligible company. Your fee will reset to $0.00.

If you are an employee of an ineligible company, please select "industry representative" and pay the industry registration fee when registering for this course. An ineligible company is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients with the exception of hospitals and facilities that provide direct care to patients.

Target Audience

  • Oncologists
  • Residents/Fellows
  • NPs/PAs
  • Pharmacists
  • Nurses

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Describe the pathogenesis, and common molecular abnormalities noted in Renal Cell
    Carcinoma (RCC).

  2. Discuss the management of localized RCC with emphasis on the role of adjuvant systemic
    therapy.

  3. Explain optimal first-line management of metastatic or advanced RCC

  4. Review the second or later lines of treatment of advanced/metastatic RCC with emphasis on molecular markers.

Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 0.00 Attendance
  • 2.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.00 Contact Hours.
Course opens: 
02/01/2021
Course expires: 
01/30/2022
Cost:
$1.00

25-minute Recording: Renal cell carcinoma: pathogenesis and molecular abnormalities - Dr. Alice Fan

25-minute Recording: Updates in localized and locally advanced renal cell carcinoma - Dr. Arpita Desai

20-minute Recording: Dr. Alice Fan & Dr. Arpita Desai - Discussion and Questions

25-minute Recording: Personalizing first-line management of advanced RCC - Dr. Toni K. Choueiri

25-minute Recording: Updates in second and later lines of management of advanced RCC – Dr. Shuchi Gulati

25-minute Recording: Dr. Toni Choueiri & Dr. Shuchi Gulati - Discussion and Questions

 

 

image

Toni K. Choueiri, MD

Director of the Lank Center for GU Oncology

Dana-Farber Cancer Institute

Learn more

image

Arpita Desai, MD

Assistant Professor

UC San Francisco 

Learn more

image

Shuchi Gulati, MD

Assistant Professor

University of Cincinnati 

Learn more

image

Alice Fan, MD

Assistant Professor

Stanford

Learn more

image

Siddhartha Yadav, MD

Assistant Professor

Mayo Clinic, Rochester, MN

Learn more

  

 

Disclosure of Off-Label Product:

This activity will include the following discussion of off-label product (s):

HIF2 inh, TKI or IO outside current indication, and not FDA approved - discussed by Dr. Toni K Choueiri

Disclosure of Relevant Financial Relationships

All relevant financial relationships have been identified and mitigated for everyone in control of the contents of this activity before their participation in this educational activity. No member of the activity planning committee or faculty has any relevant financial relationship with an ACCME defined ineligible entity with the exception of:

  • Arpita Desai, MD - Ineligible entity:  Dendreon Pharmaceuticals; Nature of relationship: Advisory Board;
  • Toni K Choueiri, MD - Ineligible entities: Pfizer, Exelixis, Roche, Merck, BMS, Roche, Novartis, GSK, Peloton; Nature of relationship: Research support and Consultant

Disclosure of Commercial Support

This activity has been supported by independent medical education grant from Exelixis, Inc. 

 

Important Information about Claiming CME for this activity:

If you participated in our live webinar on 1/31/2021 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that webinar on 1/31/2021. 


The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.

The Binaytara Foundation designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 2.0 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

Nursing Contact Hours: Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.0 Contact Hours.

 

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 0.00 Attendance
  • 2.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.00 Contact Hours.

Price

Cost:
$1.00
Please login or register to take this course.

Registration Fees:

This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0. 

Healthcare providers ($0.00)

Industry employees ($200 + 3% Credit card fee) 

If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid registrations will be invoiced $350 per participant. Sign up for this activity as an industry employee.

 

Cancellation Policy

You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations.

 

Refund Policy 

This activity is free for all healthcare providers who are not employees of an ineligible entity.

No refunds will be issued if you have started watching the recorded content.